XSpray Pharma AB (XSPRAY) - Total Liabilities
Based on the latest financial reports, XSpray Pharma AB (XSPRAY) has total liabilities worth Skr178.47 Million SEK (≈ $19.21 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore XSpray Pharma AB cash flow conversion to assess how effectively this company generates cash.
XSpray Pharma AB - Total Liabilities Trend (2015–2024)
This chart illustrates how XSpray Pharma AB's total liabilities have evolved over time, based on quarterly financial data. Check how resilient are XSpray Pharma AB's assets to evaluate the company's liquid asset resilience ratio.
XSpray Pharma AB Competitors by Total Liabilities
The table below lists competitors of XSpray Pharma AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Mikro MSC Bhd
KLSE:0112
|
Malaysia | RM19.85 Million |
|
Ctek AB
ST:CTEK
|
Sweden | Skr621.40 Million |
|
NS Co. Ltd
KQ:217820
|
Korea | ₩234.12 Billion |
|
Kuang Hong Arts Management
TWO:6596
|
Taiwan | NT$969.97 Million |
|
Noroo Paint
KO:090350
|
Korea | ₩280.30 Billion |
|
Bionet
TWO:1784
|
Taiwan | NT$855.33 Million |
|
MaxsMaking Inc. Class A Ordinary Shares
NASDAQ:MAMK
|
USA | $9.41 Million |
|
Moller Y Perez
SN:MOLLER
|
Chile | CL$249.56 Billion |
Liability Composition Analysis (2015–2024)
This chart breaks down XSpray Pharma AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see XSpray Pharma AB (XSPRAY) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.72 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.28 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.22 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how XSpray Pharma AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for XSpray Pharma AB (2015–2024)
The table below shows the annual total liabilities of XSpray Pharma AB from 2015 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | Skr173.25 Million ≈ $18.64 Million |
+141.12% |
| 2023-12-31 | Skr71.85 Million ≈ $7.73 Million |
+144.30% |
| 2022-12-31 | Skr29.41 Million ≈ $3.17 Million |
-5.59% |
| 2021-12-31 | Skr31.15 Million ≈ $3.35 Million |
+37.13% |
| 2020-12-31 | Skr22.72 Million ≈ $2.44 Million |
-15.73% |
| 2019-12-31 | Skr26.96 Million ≈ $2.90 Million |
+150.32% |
| 2018-12-31 | Skr10.77 Million ≈ $1.16 Million |
+87.17% |
| 2017-12-31 | Skr5.75 Million ≈ $619.17K |
+6.78% |
| 2016-12-31 | Skr5.39 Million ≈ $579.83K |
+100.45% |
| 2015-12-31 | Skr2.69 Million ≈ $289.27K |
-- |
About XSpray Pharma AB
Xspray Pharma AB (publ), a pharmaceutical company, engages in the development of protein kinase inhibitors for targeted cancer treatments in Sweden. The company develops Dasynoc, an amorphous version of dasatinib for the treatment of chronic myeloid leukemia (CML)and acute lymphoblastic leukemia; XS003, an amorphous non-crystalline nilotinib for the treatment of CML; XS008, an axitinib for the tr… Read more